Clinical research program : Gene-therapy by the Use of a Recombinant Adenovirus in the Treatment of p53 Deficient Cancers

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Clinical research program : Gene-therapy by the Use of a Recombinant Adenovirus in the Treatment of p53 Deficient Cancers
EU record number: 
B/BE/98/B6
Pharmaceutical study code: 
I98-102
Company / Sponsor: 
Schering Plough NV/SA
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Ovarian and primary peritoneal cancer
Therapeutic approach: 
Tumor suppressor gene
Genetic modification: 
wild-type p53 tumor suppressor gene
Method of transfer of nucleic acid of interest: 
Human Adenovirus serotype 5
Administered biological material: 
Recombinant Adenovirus D (E3, E1A, E1B, pIX)
Route of administration: 
Intraperitoneal
Locations in Belgium: 
Cliniques Universitaires Saint-Luc, Brussels - Akademisch Ziekenhuis, Vrije Universiteit Brussel - Hôpital Erasme, Brussels - Akademisch Ziekenhuis St Augustinus, Wilrijk
Nr of subjects: 
not specified (up to 360 worldwide)
Type of procedure: 
Contained use and Deliberate release
Current status: 
Authorized

Information related to the decision procedure